Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Revenue (2018 - 2025)

Historic Revenue for Whitehawk Therapeutics (WHWK) over the last 7 years, with Q1 2025 value amounting to $7.1 million.

  • Whitehawk Therapeutics' Revenue rose 3347.66% to $7.1 million in Q1 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year decrease of 4262.47%. This contributed to the annual value of $26.0 million for FY2024, which is 668.88% up from last year.
  • According to the latest figures from Q1 2025, Whitehawk Therapeutics' Revenue is $7.1 million, which was up 3347.66% from $7.2 million recorded in Q4 2024.
  • Whitehawk Therapeutics' Revenue's 5-year high stood at $14.0 million during Q4 2021, with a 5-year trough of $120000.0 in Q1 2021.
  • Moreover, its 5-year median value for Revenue was $6.0 million (2023), whereas its average is $5.8 million.
  • The largest annual percentage gain for Whitehawk Therapeutics' Revenue in the last 5 years was 182250.0% (2022), contrasted with its biggest fall of 6266.43% (2022).
  • Whitehawk Therapeutics' Revenue (Quarter) stood at $14.0 million in 2021, then tumbled by 62.66% to $5.2 million in 2022, then grew by 21.03% to $6.3 million in 2023, then grew by 14.43% to $7.2 million in 2024, then fell by 1.3% to $7.1 million in 2025.
  • Its last three reported values are $7.1 million in Q1 2025, $7.2 million for Q4 2024, and $7.2 million during Q3 2024.